Today, AstraZeneca hosted an Investor Day event, unveiling an ambitious revenue target for 2030. AstraZeneca achieves the annual revenue target of $45 billion it boasted about 10 years ago. AstraZeneca currently has five major strategic R&D centers globally, including in Europe, the United States, and China. 20 new drugs will be launched before 2030. 2030 Goal: $80 Billion Annual Revenue! Existing pipelines and future new drug launches will jointly create an 800-billion-dollar pharmaceutical giant. The future new drug launches include PCSK9 small molecule inhibitors, PD1/TIGIT, second-generation PARP inhibitors, Dato-ADC, CYP11B2 small molecule Baxdrostat, AZN ADC, etc. Powerful late-stage assets spanning oncology, cardiovascular, and metabolic fields. The oncology field will be the most important engine for AstraZeneca's growth beyond 2030! Continue to invest in disruptive industries (weight loss, ADC/RDC, next-generation IO bispecifics, cell/gene therapies) to drive growth beyond 2030! Build a strong product pipeline through external and internal innovation, including various novel drug modalities such as ADCs/RDCs, cell/gene therapies, T-cell engagers, and more. High-value new molecular formats and technology platforms will be important components of growth! Product pipeline portfolio combined with leadership in various therapeutic areas! Emerging markets outside of China have grown over 40% in the past two years! (China's growth has slowed in the past two years due to healthcare reform or anti-corruption measures.) Data from over 40 Phase III clinical trials will be available by the end of 2025, and these assets are expected to contribute approximately $20 billion in future revenue! Summary AstraZeneca, as the best-performing MNC in recent years, arguably with no rival. Once an MNC dominated by respiratory and CVMD fields, it has gradually transformed under the guidance of the 5R R&D principle, achieving a high R&D success rate. It now relies significantly on oncology while continuously advancing in other areas. Particularly, AstraZeneca has firmly established itself in the major trend of ADCs and solidly secured a leadership position in the EGFRi TKI lung cancer field. AstraZeneca has long held a leading position in the sales of prescription drugs in China's pharmaceutical market. In recent years, it has also frequently shown interest in Chinese pharmaceutical companies, such as acquiring Gracell Biotechnologies, introducing the CD3/Claudin18.2 bispecific antibody from Harbour BioMed, and the GLP-1R small molecule agonist from Eternity Bioscience.Reference: AstraZeneca Official WebsiteScan the WeChat QR code to add the editor of Antibody Circle.Those who meet the requirements can join the Antibody Circle WeChat group!Please indicate: Name + Research Direction! All reproduced articles in this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reprinted may contact us (cbplib@163.com), and we will promptly remove the content. All articles represent the views of the author and do not reflect the position of this website.
